Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
NCT01828021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2025-03-13
Summary
The purpose of this study is to determine if margetuximab is effective in the treatment of certain patients with relapsed or refractory advanced breast cancer.
Conditions
Interventions
- BIOLOGICAL
-
Margetuximab
Anti-HER2 monoclonal antibody
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2016-12-07
- Completion
- 2017-04-14
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
NCT04924699 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
NCT01304797 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
NCT00095706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
NCT01022138 ·Status: TERMINATED ·Phase: PHASE2
-
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
NCT01805908 ·Status: TERMINATED ·Phase: PHASE1
-
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
NCT00019812 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
NCT04742153 ·Status: UNKNOWN ·Phase: PHASE2
-
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
NCT00301899 ·Status: COMPLETED ·Phase: PHASE2
-
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
NCT04185311 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
NCT04170595 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Trastuzumab and Vinorelbine in Advanced Breast Cancer
NCT01185509 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
NCT00963547 ·Status: TERMINATED ·Phase: PHASE1
-
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
NCT02213744 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
NCT01290718 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00028483 ·Status: TERMINATED ·Phase: PHASE2
-
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT03135171 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
NCT02213042 ·Status: TERMINATED ·Phase: PHASE2
-
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
NCT01912963 ·Status: TERMINATED ·Phase: PHASE2
-
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00003539 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
NCT03225547 ·Status: TERMINATED ·Phase: PHASE2
-
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
NCT00106145 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
NCT00191373 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
NCT00885755 ·Status: COMPLETED ·Phase: PHASE2